Merck 2014 Annual Report Download - page 105

Download and view the complete annual report

Please find page 105 of the 2014 Merck annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 271

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200
  • 201
  • 202
  • 203
  • 204
  • 205
  • 206
  • 207
  • 208
  • 209
  • 210
  • 211
  • 212
  • 213
  • 214
  • 215
  • 216
  • 217
  • 218
  • 219
  • 220
  • 221
  • 222
  • 223
  • 224
  • 225
  • 226
  • 227
  • 228
  • 229
  • 230
  • 231
  • 232
  • 233
  • 234
  • 235
  • 236
  • 237
  • 238
  • 239
  • 240
  • 241
  • 242
  • 243
  • 244
  • 245
  • 246
  • 247
  • 248
  • 249
  • 250
  • 251
  • 252
  • 253
  • 254
  • 255
  • 256
  • 257
  • 258
  • 259
  • 260
  • 261
  • 262
  • 263
  • 264
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • 271

100 GROUP MANAGEMENT REPORT → REPORT ON ECONOMIC POSITION → Biopharmaceuticals
2014
2013
Rebif® →
Erbitux® →
Gonal-f® →
Concor® →
Glucophage® →
428
401
8.1
628
586
9.1
904
882
5.9
– 0.2
1,840
1,865
378
394
– 1.4
Euthyrox® →296
244
23.9
%
BIOPHARMACEUTICALS →
SALES AND ORGANIC GROWTH OF KEY PRODUCTS
€ million / organic growth in %
BIOPHARMACEUTICALS →
SALES AND ORGANIC GROWTH OF REBIF® AND ERBITUX® BY REGION – 2014
Total Europe North America Emerging Markets Rest of World
Rebif ®
€ million 1,839.8 698.0 970.7 138.5 32.6
Organic growth in % – 0.2 – 6.0 1.5 21.1 – 0.4
% of sales 100 38 53 7 2
Erbitux®
€ million 903.7 503.5 – 256.6 143.6
Organic growth in % 5.9 0.7 – 18.1 4.1
% of sales 100 56 – 28 16
In 2014, the Biopharmaceuticals division generated organic sales
growth of 9.1 % with Gonal-f®, the leading recombinant hormone
used in the treatment of infertility. Including adverse foreign ex-
change effects, sales increased by 7.1 % to €628 million (2013:
€ 586 million). Sales of Gonal-f® rose in all regions, with the
highest absolute growth achieved in the Emerging Markets region.
The other products in the Fertility portfolio also developed posi-
tively.
At €394 million, sales by the Endocrinology franchise, which
mainly consists of products to treat metabolic and growth disor-
ders, reached the year-earlier figure. Organic growth of 2.0 % was
offset by negative foreign exchange effects. Sales of the growth
hormone Saizen®, the top-selling product of this franchise, saw an
organic increase of 4.0 % as well as negative foreign exchange
effects of – 3.3 %. Consequently, sales amounted to €237 million
(2013: €235 million).
The Biopharmaceuticals division’s General Medicine franchise (in-
cluding Cardio Metabolic Care), which consists of products to treat
cardiovascular diseases and diabetes, among others, generated or-
ganic sales growth of 3.9 %. Including negative foreign exchange
effects, sales amounted to €1,671 million (2013: €1,643 million).
In particular, the organic sales growth of the beta-blocker Concor®
and organic sales of products to treat thyroid disorders (Euthy-
rox®) developed well. The decline in sales of Glucophage®, which
is used to treat diabetes, to €378 million (2013: €394) was large-
ly due to the impact of negative currency effects in the first half
of 2014, as well as supply constraints in Europe.